Back to School: How biopharma can reboot drug development. Access exclusive analysis here

XMT-1001: Interim Phase I data

Interim data from 12 patients in an open-label, dose-ranging Phase

Read the full 108 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE